GLEN ALLEN, Va.--(BUSINESS WIRE)--Bostwick Laboratories, Inc., the largest provider of urologic anatomic pathology laboratory services in the United States, today announced a majority investment by Metalmark Capital, a New York-based private equity firm. Founder and CEO, Dr. David G. Bostwick, will continue to be a major shareholder in Bostwick Laboratories. Metalmark’s investment in Bostwick Laboratories will provide the capital needed to pursue its growth initiatives and expand development of its pathology laboratory services, which specialize in the monitoring and diagnosis of cancer. Financial terms of the deal were not disclosed.
